Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

Also called NCT01478971

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 184 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01478971
  • WHO UTN U1111-1150-2575
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01478971. Allocation not applicable; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
Acronym
DIAMOND
Condition
Anemia
Intervention (Drug)
Epoetin
Intervention (Drug)
Peginesatide
Lead sponsor
Takeda (class: industry)
Collaborator
Affymax (class: industry)

Record details

Record id
cardio:ct-nct01478971
Content hash
8f6dbc2088d43847404e78969f7a34f9a213cfb9fa9ad2680a92e223ddf8a2ff